FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130184865> ?p ?o ?g. }

• W2130184865 endingPage "526" @default.
• W2130184865 startingPage "514" @default.
• W2130184865 abstract "Background: Besifloxacin ophthalmic suspension 0.6% is a new topical fluoroquinolone for the treatment of bacterial conjunctivitis. Besifloxacin has potent in vitro activity against a broad spectrum of ocular pathogens, including drug-resistant strains. Objective: The primary objective of this study was to compare the clinical and microbiologic efficacy of besifloxacin ophthalmic suspension 0.6% with that of vehicle (the formulation without besifloxacin) in the treatment of bacterial conjunctivitis. Methods: This was a multicenter, prospective, randomized, double-masked, vehicle-controlled, parallel-group study in patients with acute bacterial conjunctivitis. Patients received either topical besifloxacin ophthalmic suspension or vehicle administered 3 times daily for 5 days. At study entry and on days 4 and 8 (visits 2 and 3), a clinical assessment of ocular signs and symptoms was performed in both eyes, as well as pinhole visual acuity testing, biomicroscopy, and culture of the infected eye(s). An ophthalmoscopic examination was performed at study entry and on day 8. The primary efficacy outcome measures were clinical resolution and eradication of the baseline bacterial infection on day 8 in culture-confirmed patients. The safety evaluation included adverse events, changes in visual acuity, and biomicroscopy and ophthalmoscopy findings in all patients who received at least 1 dose of active treatment or vehicle. Results: The safety population consisted of 269 patients (mean [SD] age, 34.2 [22.3] years; 60.2% female; 82.5% white) with acute bacterial conjunctivitis. The culture-confirmed intent-to-treat population consisted of 118 patients (60 besifloxacin ophthalmic suspension, 58 vehicle). Significantly more patients receiving besifloxacin ophthalmic suspension than vehicle had clinical resolution of the baseline infection at visit 3 (44/60 [73.3%] vs 25/58 [43.1%], respectively; P < 0.001). Rates of bacterial eradication also were significantly greater with besifloxacin ophthalmic suspension compared with vehicle at visit 3 (53/60 [88.3%] vs35/58 [60.3%]; P < 0.001). The cumulative frequency of adverse events did not differ significantly between the 2 groups (69/137 [50.4%] and 70/132 [53.0%]). The most common ocular adverse events were eye pain (20/190 treated eyes [10.5%] and 13/188 [6.9%]), blurred vision (20/190 [10.5%] and 22/188 [11.7%]), and eye irritation (14/190 [7.4%] and 23/188 [12.2%]); these events were of mild or moderate severity. Changes in visual acuity and treatment-emergent events observed on biomicroscopy and direct ophthalmoscopy also were comparable between treatment groups. Conclusion: Besifloxacin ophthalmic suspension 0.6% given 3 times daily for 5 days was both efficacious and well tolerated compared with vehicle in the treatment of these patients with bacterial conjunctivitis." @default.
• W2130184865 created "2016-06-24" @default.
• W2130184865 creator A5002443207 @default.
• W2130184865 creator A5010851613 @default.
• W2130184865 creator A5050362359 @default.
• W2130184865 creator A5056356350 @default.
• W2130184865 creator A5070789852 @default.
• W2130184865 creator A5077067378 @default.
• W2130184865 creator A5079866511 @default.
• W2130184865 creator A5087815671 @default.
• W2130184865 creator A5088888181 @default.
• W2130184865 date "2009-03-01" @default.
• W2130184865 modified "2023-09-27" @default.
• W2130184865 title "Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study" @default.
• W2130184865 cites W119962265 @default.
• W2130184865 cites W1975053437 @default.
• W2130184865 cites W1984207232 @default.
• W2130184865 cites W1990911266 @default.
• W2130184865 cites W1990915680 @default.
• W2130184865 cites W1993182636 @default.
• W2130184865 cites W1999614061 @default.
• W2130184865 cites W2000441785 @default.
• W2130184865 cites W2000814575 @default.
• W2130184865 cites W2017763305 @default.
• W2130184865 cites W2024518344 @default.
• W2130184865 cites W2026395354 @default.
• W2130184865 cites W2031888076 @default.
• W2130184865 cites W2033774432 @default.
• W2130184865 cites W2050519642 @default.
• W2130184865 cites W2061066154 @default.
• W2130184865 cites W2069221293 @default.
• W2130184865 cites W2070449956 @default.
• W2130184865 cites W2075175082 @default.
• W2130184865 cites W2080741495 @default.
• W2130184865 cites W2093600524 @default.
• W2130184865 cites W2109726963 @default.
• W2130184865 cites W2124899117 @default.
• W2130184865 cites W2132326533 @default.
• W2130184865 cites W2135465392 @default.
• W2130184865 cites W2136480024 @default.
• W2130184865 cites W2138504093 @default.
• W2130184865 cites W2414285739 @default.
• W2130184865 cites W4235453801 @default.
• W2130184865 cites W4406338 @default.
• W2130184865 doi "https://doi.org/10.1016/j.clinthera.2009.03.010" @default.
• W2130184865 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19393842" @default.
• W2130184865 hasPublicationYear "2009" @default.
• W2130184865 type Work @default.
• W2130184865 sameAs 2130184865 @default.
• W2130184865 citedByCount "72" @default.
• W2130184865 countsByYear W21301848652012 @default.
• W2130184865 countsByYear W21301848652013 @default.
• W2130184865 countsByYear W21301848652014 @default.
• W2130184865 countsByYear W21301848652015 @default.
• W2130184865 countsByYear W21301848652016 @default.
• W2130184865 countsByYear W21301848652017 @default.
• W2130184865 countsByYear W21301848652018 @default.
• W2130184865 countsByYear W21301848652019 @default.
• W2130184865 countsByYear W21301848652020 @default.
• W2130184865 countsByYear W21301848652021 @default.
• W2130184865 countsByYear W21301848652022 @default.
• W2130184865 countsByYear W21301848652023 @default.
• W2130184865 crossrefType "journal-article" @default.
• W2130184865 hasAuthorship W2130184865A5002443207 @default.
• W2130184865 hasAuthorship W2130184865A5010851613 @default.
• W2130184865 hasAuthorship W2130184865A5050362359 @default.
• W2130184865 hasAuthorship W2130184865A5056356350 @default.
• W2130184865 hasAuthorship W2130184865A5070789852 @default.
• W2130184865 hasAuthorship W2130184865A5077067378 @default.
• W2130184865 hasAuthorship W2130184865A5079866511 @default.
• W2130184865 hasAuthorship W2130184865A5087815671 @default.
• W2130184865 hasAuthorship W2130184865A5088888181 @default.
• W2130184865 hasConcept C118487528 @default.
• W2130184865 hasConcept C126322002 @default.
• W2130184865 hasConcept C141071460 @default.
• W2130184865 hasConcept C16005928 @default.
• W2130184865 hasConcept C168563851 @default.
• W2130184865 hasConcept C188816634 @default.
• W2130184865 hasConcept C197934379 @default.
• W2130184865 hasConcept C2778257484 @default.
• W2130184865 hasConcept C2908647359 @default.
• W2130184865 hasConcept C2908692415 @default.
• W2130184865 hasConcept C501593827 @default.
• W2130184865 hasConcept C535046627 @default.
• W2130184865 hasConcept C71924100 @default.
• W2130184865 hasConcept C86803240 @default.
• W2130184865 hasConcept C89423630 @default.
• W2130184865 hasConcept C99454951 @default.
• W2130184865 hasConceptScore W2130184865C118487528 @default.
• W2130184865 hasConceptScore W2130184865C126322002 @default.
• W2130184865 hasConceptScore W2130184865C141071460 @default.
• W2130184865 hasConceptScore W2130184865C16005928 @default.
• W2130184865 hasConceptScore W2130184865C168563851 @default.
• W2130184865 hasConceptScore W2130184865C188816634 @default.
• W2130184865 hasConceptScore W2130184865C197934379 @default.
• W2130184865 hasConceptScore W2130184865C2778257484 @default.
• W2130184865 hasConceptScore W2130184865C2908647359 @default.
• W2130184865 hasConceptScore W2130184865C2908692415 @default.

• next